3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
Status:
Completed
Trial end date:
2020-02-10
Target enrollment:
Participant gender:
Summary
This was a multicenter, randomized, phase II study evaluating Everolimus or Pasireotide LAR
alone or in combination in adult patients with advanced (unresectable or metastatic)
neuroendocrine carcinoma of the lung and thymus